Immunodeficiency 101 (Varicella-Zoster Virus–Specific): Disease Characteristics Report

Executive summary and evidence limitations

Immunodeficiency 101, varicella-zoster virus–specific is best mapped to an ultra-rare, Mendelian, selective susceptibility to severe varicella-zoster virus (VZV) disease caused by a monoallelic POLR3F defect. The defining report described two monozygotic adult female twins with recurrent VZV-associated central nervous system (CNS) vasculitis and a heterozygous POLR3F c.25C>T (p.Arg50Trp; R50W) variant. Patient peripheral-blood mononuclear cells (PBMCs) had deficient responses to AT-rich DNA and increased VZV replication, connecting the genotype to impaired RNA polymerase III (Pol III) antiviral sensing. This is distinct from the broader group of Pol III–related VZV susceptibilities caused by POLR3A, POLR3C, or POLR3E variants. (cartertimofte2018varicellazosterviruscns pages 6-8, cartertimofte2018varicellazosterviruscns pages 4-5, ansari2021primaryandacquired pages 5-6)

The evidence base is exceptionally small: two molecularly confirmed POLR3F-affected individuals from one family. Consequently, phenotype frequencies, penetrance, prevalence, survival, treatment-response rates, sex ratio, and genotype–phenotype correlations cannot be estimated reliably. No clearly documented additional POLR3F-specific cases were found in the retrieved 2023–2024 literature. Most disease-specific evidence is therefore human case-level evidence supplemented by ex vivo PBMC studies and broader VZV/Pol III reviews.

Table: This table summarizes the highest-confidence evidence for Immunodeficiency 101 (VZV-specific), best mapped here to POLR3F-related selective susceptibility to severe VZV CNS disease. It highlights what is known from primary human cases and reviews, while clearly marking major unresolved gaps.

1. Disease information

Definition

This condition is an inborn error of intrinsic/innate antiviral immunity in which defective POLR3F-containing RNA polymerase III compromises recognition of the AT-rich VZV genome. Clinically, the reported phenotype is recurrent VZV reactivation in the CNS, causing meningoencephalitis/vasculitis, ischemic lesions, and stroke-like neurologic episodes despite an otherwise normal routine immune evaluation. The patients did not exhibit broad susceptibility to bacterial, fungal, or unrelated viral infections. (cartertimofte2018varicellazosterviruscns pages 1-2, cartertimofte2018varicellazosterviruscns pages 4-5)

Names and identifiers

• Preferred label: Immunodeficiency 101, varicella-zoster virus–specific.
• Useful synonyms: POLR3F-related VZV susceptibility; POLR3F deficiency; RNA polymerase III deficiency due to POLR3F; selective susceptibility to severe VZV infection; VZV CNS vasculitis associated with POLR3F mutation.
• Gene: POLR3F, encoding RNA polymerase III subunit F/RPC6.
• MONDO, OMIM phenotype, Orphanet: a stable disease-level identifier could not be verified from the retrieved full-text sources; it should therefore not be inferred from the numbered disease label alone.
• ICD-10/ICD-11: no disease-specific code was identified. Component manifestations may be coded as hereditary immunodeficiency, viral encephalitis/meningitis, cerebral vasculitis, or VZV infection, depending on the coding system and confirmed presentation.
• MeSH: relevant concepts include Immunologic Deficiency Syndromes, Herpesvirus 3, Human, Encephalitis, Viral, and Central Nervous System Vasculitis.

The source is aggregated disease-level interpretation derived primarily from two individual patients, not an EHR cohort or population registry.

Foundational evidence

Carter-Timofte et al., “Varicella-zoster virus CNS vasculitis and RNA polymerase III gene mutation in identical twins,” Neurology: Neuroimmunology & Neuroinflammation, volume 5, published November 2018, DOI: 10.1212/NXI.0000000000000500. PMID was not available in the retrieved text and is not supplied here to avoid an unverified identifier. (cartertimofte2018varicellazosterviruscns pages 6-8)

A direct abstract statement is: “The identified R50W POLR3F mutation is predicted by bioinformatics to be damaging, and when tested in functional assays, patient PBMCs exhibited impaired antiviral and inflammatory responses to the POL III agonist poly(dA:dT) and increased viral replication compared with controls.” (cartertimofte2018varicellazosterviruscns pages 1-2)

2. Etiology, risk factors, and protective factors

Causal factors

The proximal inherited cause is the heterozygous POLR3F p.Arg50Trp variant. The necessary infectious trigger is exposure to and subsequent latency/reactivation of VZV, a human alphaherpesvirus. Both twins reportedly had ordinary childhood varicella; their severe phenotype emerged later during viral reactivation rather than during primary infection. (cartertimofte2018varicellazosterviruscns pages 3-4, cartertimofte2018varicellazosterviruscns pages 4-5)

Genetic risk

The reported variant was inherited from the father, who had a previous stroke that the authors considered possibly compatible with VZV CNS vasculitis. This segregation supports autosomal-dominant susceptibility but does not establish complete penetrance. The variant had a reported CADD score of 25.8, above the cited significance threshold of 13, and was predicted damaging. Its expression and solubility were not materially altered, favoring impaired molecular function rather than protein instability. (cartertimofte2018varicellazosterviruscns pages 4-5)

Other genes—POLR3A, POLR3C, and POLR3E—cause related Pol III–dependent VZV susceptibility, but they should not be recorded as causal genes for the narrowly defined POLR3F-specific entity. Across the wider syndrome, VZV-associated Pol III variants map mainly near DNA-binding/initiation or catalytic regions, unlike many biallelic variants causing POLR3-related hypomyelinating leukodystrophy. (lata2021rnapolymeraseiii pages 21-22, cartertimofte2018rnapolymeraseiii pages 6-8)

Environmental and acquired modifiers

VZV infection is indispensable. General factors that impair VZV control—aging, HIV, hematologic disease, transplantation, immunosuppressive drugs, and T/NK-cell deficiencies—can independently increase severe VZV risk, but none was demonstrated as causal in the twins. Their immunoglobulins, lymphocyte distribution/proliferation, and HIV testing were normal. (kennedy2021recentissuesin pages 8-9, cartertimofte2018varicellazosterviruscns pages 4-5)

No disease-specific evidence supports smoking, diet, alcohol, exercise, occupational exposure, toxins, radiation, sex, or ancestry as modifiers.

Protective factors and gene–environment interaction

Antiviral prophylaxis appeared protective in the reported family: both twins received acyclovir prophylaxis, and one developed recurrent symptoms and new white-matter lesions after discontinuation. Expert review—not controlled trial evidence—suggests varicella vaccination in childhood, recombinant zoster vaccination in adulthood, and antiviral prophylaxis after severe or recurrent CNS disease. (cartertimofte2018varicellazosterviruscns pages 6-8, cartertimofte2018rnapolymeraseiii pages 10-11)

The causal interaction is: monoallelic POLR3F dysfunction + latent/reactivating VZV → inadequate AT-rich DNA sensing → deficient interferon response → excessive viral replication → CNS arterial infection/inflammation and ischemia. Ordinary VZV exposure is therefore usually benign in the population but becomes pathogenic in the genetically susceptible host. (cartertimofte2018rnapolymeraseiii pages 6-8, ansari2021primaryandacquired pages 5-6)

3. Phenotypes

Because only two twins are confirmed, “2/2” means occurrence in the index family, not a generalizable population frequency.

The reported clinical picture included headache, dizziness, neurologic deficits, CSF pleocytosis with intrathecal VZV antibody production, and ischemic brain lesions. One summary reports paraventricular parietal and bilateral juxtacortical lesions and cervical–upper thoracic myelitis. (cartertimofte2018varicellazosterviruscns pages 1-2, cartertimofte2018varicellazosterviruscns pages 3-4)

Quality-of-life instruments were not administered. Nevertheless, recurrent stroke-like events, hospitalization, neurologic impairment, repeated lumbar puncture/imaging, and chronic antiviral use imply potentially major functional and psychosocial burden. Quantified EQ-5D, SF-36, PROMIS, educational, employment, and caregiver outcomes are unavailable.

4. Genetic and molecular information

Causal gene and variant

• Gene: POLR3F.
• Protein: RNA polymerase III subunit F/RPC6, part of the Pol III initiation-associated peripheral subcomplex.
• Reported variant: c.25C>T, p.Arg50Trp (R50W), heterozygous and germline.
• Variant class: missense, monoallelic.
• Functional interpretation: loss/hypomorphic impairment of antiviral DNA sensing is supported; a dominant-negative mechanism was not established.
• Computational evidence: CADD 25.8 and damaging predictions.
• Protein studies: mutant abundance/solubility was reportedly preserved, suggesting altered ligand recognition, initiation, or enzyme activity rather than degradation. (cartertimofte2018varicellazosterviruscns pages 4-5)

The primary paper called the variant novel. A precise modern gnomAD allele count, rsID, ClinVar accession, ACMG/AMP classification, HGNC ID, and transcript version were not established by the retrieved evidence. It should not automatically be labeled “pathogenic” in a clinical database without checking current ClinVar/ClinGen submissions and transcript-specific HGVS normalization. The case data provide strong phenotype, segregation, computational, and functional support but remain limited to one family.

Broader allelic and mechanistic context

Heterozygous VZV-susceptibility variants reported in the larger Pol III group include POLR3A M307V, R437Q, R582C and Q707R; POLR3C L11F, R84Q and R438G; POLR3E T275M; and POLR3F R50W. POLR3F R50W was associated specifically with adult reactivation and CNS vasculitis, whereas POLR3A/C variants also caused childhood encephalitis, cerebellitis, or pneumonitis during primary infection. (cartertimofte2018rnapolymeraseiii pages 6-8)

No validated POLR3F modifier gene, protective allele, founder mutation, germline mosaicism, anticipation, somatic mutation, copy-number abnormality, translocation, inversion, or aneuploidy has been reported for this phenotype. No disease-specific methylation, histone, chromatin, or imprinting abnormality is known.

5. Environmental and infectious information

The direct non-genetic agent is varicella-zoster virus (human alphaherpesvirus 3; NCBI Taxonomy identification should be attached at the pathogen record level). Primary infection produces varicella; lifelong latency is established in sensory, cranial, and autonomic ganglionic neurons; reactivation can produce zoster or neurologic disease. The POLR3F cases represent neurologic reactivation, potentially without reliance on a contemporaneous typical rash. (kennedy2021recentissuesin pages 8-9, cartertimofte2018rnapolymeraseiii pages 1-2)

No toxin, pollutant, radiation, dietary, occupational, smoking, alcohol, or exercise association is known. Immunosuppression and aging are important general VZV modifiers but were not defining features of these patients.

6. Mechanism and pathophysiology

Causal chain

1. Trigger: latent VZV reactivates and viral AT-rich DNA becomes available to intracellular sensing.
2. Upstream lesion: POLR3F p.Arg50Trp impairs the cytoplasmic antiviral function of the 17-subunit RNA polymerase III complex.
3. Normal pathway: Pol III transcribes AT-rich DNA into 5′-triphosphorylated RNA, which activates RIG-I, then MAVS, IRF/NF-κB signaling, and type I/III interferon production.
4. Patient-cell defect: poly(dA:dT)-induced antiviral and inflammatory responses, including IFN-β and TNF-α, are reduced; VZV gene expression/replication rises.
5. Tissue consequence: inadequate viral restriction permits infection and inflammation involving CNS tissue and cerebral arterial walls.
6. Clinical consequence: vasculopathy, vessel narrowing/ischemia, headache, sensory or motor deficits, and recurrent stroke-like episodes. (cartertimofte2018rnapolymeraseiii pages 4-6, cartertimofte2018rnapolymeraseiii pages 6-8, ansari2021primaryandacquired pages 5-6)

Nuclear Pol III normally transcribes tRNAs, 5S rRNA, U6 snRNA, and other small RNAs. In VZV-susceptibility patients, housekeeping transcription such as 5S rRNA production was preserved, helping explain the narrow infectious phenotype and distinguishing it from biallelic POLR3-related leukodystrophy. (lata2021rnapolymeraseiii pages 21-22, cartertimofte2018rnapolymeraseiii pages 4-6)

Cells, tissues, and ontology suggestions

Experimentally studied: PBMCs, including mixed lymphoid and myeloid populations. Biologically plausible but not directly proven in the twins: monocytes/macrophages, cerebral endothelial or vascular smooth-muscle cells, neurons, microglia, astrocytes, and dermal fibroblasts. Reviews explicitly identify the decisive in-vivo cell type and the site at which Pol III controls latency/reactivation as unresolved. (kennedy2021recentissuesin pages 8-9, cartertimofte2018rnapolymeraseiii pages 10-11)

Suggested GO biological processes include:

• cytoplasmic pattern-recognition receptor signaling pathway in response to virus;
• defense response to virus (GO:0051607);
• type I interferon production (GO:0032606);
• response to type I interferon (GO:0034340);
• RNA polymerase III transcription;
• negative regulation of viral genome replication;
• RIG-I signaling pathway;
• inflammatory response and regulation of cytokine production.

Suggested cellular components include cytosol (GO:0005829), nucleus (GO:0005634), RNA polymerase III complex, and mitochondrial outer membrane/MAVS signaling platform. Suggested CL mappings include peripheral-blood mononuclear cell, monocyte (CL:0000576), T cell (CL:0000084), B cell (CL:0000236), natural killer cell (CL:0000623), neuron (CL:0000540), microglial cell (CL:0000129), astrocyte (CL:0000127), and vascular endothelial cell. These are knowledge-base mappings, not all directly demonstrated disease cell types.

Molecular profiling and advanced technologies

Disease-specific bulk or single-cell transcriptomics, spatial transcriptomics, proteomics, metabolomics, lipidomics, epigenomics, and multi-omics datasets were not found. The available molecular profile consists principally of targeted cytokine measurements and VZV gene-expression/replication assays in patient PBMCs. No disease-specific CRISPR screen or patient-derived iPSC/organoid model was identified.

Recent structural work on human Pol III supports the broader interpretation that viral-sensing variants are situated near DNA-interacting regions, whereas neurodevelopmental variants tend to affect enzyme stability or biogenesis. This provides structural plausibility but is not a POLR3F-p.Arg50Trp clinical validation by itself. (lata2021rnapolymeraseiii pages 21-22, lata2021rnapolymeraseiii pages 10-11)

7. Anatomical structures affected

• Primary system: nervous system.
• Organs: brain and spinal cord; meninges may be involved through meningoencephalitic disease.
• Vascular structures: intracranial/cerebral arteries affected by VZV vasculopathy.
• Sites reported: parietal periventricular/paraventricular and juxtacortical cerebral white matter; cervical-to-upper-thoracic spinal cord, approximately C6–T2, in one patient.
• Secondary structures in VZV biology: dorsal-root, cranial, and autonomic ganglia harbor latent virus.
• Lateralization: neurologic deficits can be unilateral, but imaging lesions may be bilateral or multifocal. (kennedy2021recentissuesin pages 8-9, cartertimofte2018varicellazosterviruscns pages 3-4)

Suggested UBERON mappings include brain (UBERON:0000955), spinal cord (UBERON:0002240), central nervous system (UBERON:0001017), cerebral artery, cerebral white matter, meninges, dorsal-root ganglion, and blood-vessel wall. At the subcellular level, both cytosolic immune sensing and nuclear housekeeping Pol III functions are relevant.

8. Temporal development

The twins had uncomplicated primary varicella in childhood and developed recurrent CNS disease in adulthood. Review summaries describe both as 37-year-old women; patient-level summaries indicate initial presentations at approximately 25 and 35 years, reflecting differing episode histories or ages at first documented presentation. The disorder should therefore be modeled as genetic from conception but clinically latent until VZV reactivation, with variable adult onset. (cartertimofte2018rnapolymeraseiii pages 6-8, cartertimofte2018varicellazosterviruscns pages 3-4)

The clinical course is acute-to-subacute during each neurologic attack but lifelong and relapsing at the susceptibility level. Remission can follow antiviral treatment, while stopping prophylaxis may permit recurrence. No formal disease stages, median recurrence interval, critical developmental window, or long-term natural-history curve has been established. (cartertimofte2018varicellazosterviruscns pages 6-8)

9. Inheritance and population

Inheritance

The best-supported model is autosomal dominant/monoallelic susceptibility with incomplete or context-dependent penetrance. Both monozygotic twins inherited the allele from their father; his possible VZV-related stroke suggests expression but is not a molecularly confirmed third case. Because VZV exposure/reactivation and additional immune factors are required, penetrance is likely infection- and age-dependent. (cartertimofte2018varicellazosterviruscns pages 4-5)

There is no evidence for anticipation, a founder effect, consanguinity dependence, or a sex-limited phenotype. The occurrence in female twins cannot establish a female predominance.

Epidemiology

• Confirmed disease-specific patients: 2.
• Families: 1.
• Prevalence/incidence: unknown; no registry or population estimate.
• Carrier frequency: unknown.
• Geographic/ancestral distribution: insufficiently reported.
• Sex ratio: indeterminate.

The condition is appropriately classified as ultra-rare, but a numerical prevalence per 100,000 cannot be justified.

10. Diagnostics

Clinical recognition

Consider the disorder in an otherwise healthy person with recurrent or unusually severe VZV meningoencephalitis, CNS vasculopathy, myelitis, ischemic stroke, pneumonitis, or disseminated disease—particularly with normal routine immune testing or a family history of similar neurologic events. Recurrent VZV CNS disease is a stronger warning sign than uncomplicated zoster.

Acute VZV/CNS evaluation

Recommended evaluation is phenotype-driven and includes:

1. Brain MRI with diffusion-weighted and vascular imaging; spinal MRI if myelopathy is present.
2. Lumbar puncture with cell count, protein/glucose, VZV PCR, and paired serum/CSF anti-VZV IgG to demonstrate intrathecal synthesis.
3. Recognition that negative CSF VZV PCR does not exclude vasculopathy; intrathecal anti-VZV IgG may remain positive and can be more sensitive in protracted disease. The affected twin had pleocytosis and intrathecal VZV IgG despite negative PCR. (cartertimofte2018varicellazosterviruscns pages 3-4)
4. Baseline immune assessment: complete blood count/differential, quantitative immunoglobulins, lymphocyte subsets and proliferation, HIV testing, and evaluation for acquired immunosuppression. These tests were normal in the reported patients. (cartertimofte2018varicellazosterviruscns pages 4-5)

Genetic testing

• Preferred approach: an inborn-error-of-immunity or severe viral-infection panel containing POLR3F, POLR3A, POLR3C, POLR3E, and relevant differential genes; alternatively WES/WGS.
• Confirmation: Sanger or orthogonal confirmation, parental testing, segregation analysis, transcript-specific HGVS normalization, and current ClinVar/gnomAD review.
• Functional support: PBMC stimulation with poly(dA:dT), measurement of IFN-β/type I or III IFN and inflammatory cytokines, and VZV replication/gene-expression assays. These remain specialized research tests rather than standardized clinical diagnostics. (cartertimofte2018varicellazosterviruscns pages 6-8, ansari2021primaryandacquired pages 5-6)
• CMA, karyotype, FISH, mitochondrial testing, and repeat-expansion testing: low expected yield for an isolated missense disorder unless another phenotype suggests a structural or mitochondrial diagnosis.
• RNA sequencing: not validated diagnostically for p.Arg50Trp; it may help evaluate splice or expression variants in unsolved cases.

Differential diagnosis

Important alternatives include acquired immunosuppression/HIV; hematologic malignancy or transplantation; anti-type-I-IFN autoantibodies; broad T/NK-cell defects such as GATA2, DOCK2, DOCK8, STK4, MAGT1, CXCR4, STAT1/STAT3/STAT5B-associated disorders; TLR3-pathway defects; other Pol III subunit defects; antiphospholipid or primary autoimmune vasculitis; atherosclerotic/dissection-related stroke; multiple sclerosis and other inflammatory myelitis; HSV encephalitis; and non-VZV infectious vasculopathies. Broader immunodeficiencies usually produce additional infections or characteristic immunologic abnormalities, whereas POLR3F disease was narrowly VZV-specific. (kennedy2021recentissuesin pages 8-9, ansari2021primaryandacquired pages 21-22, ansari2021primaryandacquired pages 24-25, ansari2021primaryandacquired pages 22-23)

No newborn or population screening is indicated. Once a familial pathogenic/likely pathogenic variant is established, cascade testing is reasonable with careful counseling about uncertain penetrance.

11. Outcome and prognosis

Disease-specific survival, mortality, life expectancy, and five- or ten-year outcomes are unknown. Both reported patients survived recurrent attacks and received prophylaxis, but ischemic lesions and recurring neurologic deficits indicate a risk of cumulative disability. One twin developed renewed symptoms and new white-matter lesions after stopping prophylaxis. (cartertimofte2018varicellazosterviruscns pages 6-8)

Prognosis probably depends on rapid antiviral treatment, recurrence prevention, lesion burden and location, presence of large-vessel vasculopathy or myelitis, and residual motor/cognitive deficits. These are clinically plausible factors rather than validated POLR3F prognostic models. No prognostic biomarker beyond virologic activity, CSF inflammation, and imaging has been validated.

12. Treatment

Acute disease

In the reported family, treatment included intravenous acyclovir 10 mg/kg every eight hours for 14 days and prednisolone 50 mg/day for 10 days. This targets viral replication and presumed arterial inflammation, respectively. (cartertimofte2018varicellazosterviruscns pages 3-4)

Suggested NCIt mappings include Acyclovir (NCIt drug concept), antiviral therapy, corticosteroid therapy, and supportive care. Renal function and hydration should be monitored during intravenous acyclovir; dose adjustment is required for kidney impairment. Steroids should not replace antiviral therapy and should be individualized because disease-specific controlled evidence is absent.

Long-term strategy

Both twins received suppressive acyclovir. Expert review recommends considering acyclovir prophylaxis after severe or recurrent CNS disease and age-appropriate varicella/zoster immunization in Pol III defects. The recurrence observed after prophylaxis discontinuation supports continued suppression in this family, but optimal drug, dose, and duration are unknown. (cartertimofte2018varicellazosterviruscns pages 6-8, cartertimofte2018rnapolymeraseiii pages 10-11)

Experimental and precision therapies

No POLR3F-specific interventional trial, gene therapy, gene editing, RNA therapy, hematopoietic stem-cell transplantation protocol, or adoptive VZV-specific T-cell trial was identified. Interferon therapy has been proposed more broadly for selected IFN-pathway defects, and IFN-α/IFN-γ inhibit VZV in vitro, but this is not established treatment for POLR3F deficiency. (ansari2021primaryandacquired pages 10-11)

A rational current algorithm is: suspected VZV CNS disease → collect CSF and imaging promptly without delaying IV acyclovir → consider adjunct corticosteroid for vasculopathy → confirm intrathecal VZV immunity/PCR → investigate immune and genetic causes → institute individualized long-term antiviral suppression and rehabilitation.

13. Prevention

Primary prevention

Preventing primary VZV infection through routine varicella vaccination is biologically attractive, but the safety and efficacy of live-attenuated varicella vaccine in a known POLR3F carrier have not been studied. Decisions should be made with clinical immunology and infectious-disease specialists after assessing immune competence. Expert review also advocates adult zoster vaccination, especially a non-live recombinant subunit vaccine, although direct POLR3F data are unavailable. (cartertimofte2018rnapolymeraseiii pages 10-11)

Secondary and tertiary prevention

• Educate carriers to seek urgent care for headache, focal deficits, altered consciousness, myelopathic symptoms, or zoster-associated neurologic symptoms.
• Use rapid CSF/imaging evaluation and early antiviral treatment.
• Consider long-term acyclovir/valacyclovir suppression after recurrent CNS disease.
• Monitor renal toxicity and antiviral adherence.
• Use physical, occupational, speech, visual, or neuropsychological rehabilitation according to residual deficits.
• Offer cascade genetic testing and counseling to adult relatives once variant pathogenicity is clinically accepted.

Prenatal or preimplantation testing is technically possible for a known familial variant, but uncertain penetrance and a potentially preventable/treatable infectious phenotype require nuanced counseling. No population carrier-screening program is justified.

14. Other species and natural disease

VZV is highly human-restricted; no naturally occurring veterinary counterpart of human POLR3F-specific VZV immunodeficiency was identified. Therefore, breed ontology entries, veterinary prevalence, zoonotic transmission, and natural cross-species disease are not applicable.

Simian varicella virus in rhesus macaques resembles human primary and reactivated VZV disease and has demonstrated an important role for CD4 T-cell immunity, but it is an analog infection rather than a natural POLR3F-deficiency model. Small-animal VZV inoculation can establish ganglionic infection without faithfully reproducing human rash or the full neurologic syndrome. Human tissue xenografts in SCID mice and simian varicella models are useful for VZV neurotropism, latency, and immunity research. These systems do not yet recapitulate the human POLR3F p.Arg50Trp genotype. (cartertimofte2018rnapolymeraseiii pages 10-11)

POLR3F and the Pol III machinery are evolutionarily conserved, but specific ortholog identifiers and a naturally occurring orthologous animal syndrome were not established by the retrieved evidence.

15. Model organisms and experimental models

Available models

• Patient PBMCs: the most disease-specific model; they reproduce deficient poly(dA:dT)-induced cytokine responses and increased VZV replication. Strength: direct human genotype–phenotype relevance. Limitation: mixed circulating cells do not reproduce neurons, ganglia, cerebral arteries, or tissue-resident immunity. (cartertimofte2018varicellazosterviruscns pages 6-8, ansari2021primaryandacquired pages 5-6)
• Recombinant/expression assays: mutant POLR3F expression and solubility can be compared with wild type. Strength: tests protein stability; limitation: does not capture the intact tissue response. (cartertimofte2018varicellazosterviruscns pages 4-5)
• SCID-human xenografts: human skin or neural tissue implanted in immunodeficient mice supports VZV pathogenesis studies. Strength: human-tissue tropism; limitation: lacks an intact human immune system and has not been engineered for p.Arg50Trp.
• Rhesus macaque/simian varicella virus: reproduces key features of primary infection, latency, and reactivation. Strength: intact primate immunity; limitation: different virus and no reported POLR3F disease genotype.
• Standard small animals: limited because human VZV is species-restricted and generally fails to reproduce the complete human phenotype.

Needed next-generation models

Priority models include CRISPR knock-in of POLR3F p.Arg50Trp in human iPSCs differentiated into neurons, microglia, astrocytes, and cerebral endothelial cells; vascular organoids combining these cell types; isogenic rescue lines; and a conditional knock-in mammalian model challenged with an appropriate alphaherpesvirus. Single-cell transcriptomics and spatial profiling across infected neurovascular units could determine which cells fail to mount Pol III–RIG-I–MAVS interferon responses.

Recent developments, expert assessment, and knowledge gaps

Research in 2023 broadened host-genetic investigation of severe alphaherpesvirus disease: WES of 17 patients with HSV- or VZV-induced acute retinal necrosis identified 50 potentially disease-associated variants in 16/17, concentrated in innate/adaptive immunity, autophagy, and apoptosis pathways. This does not establish new POLR3F cases, but it supports systematic genomic evaluation of unusually severe, tissue-restricted VZV disease. The study was published October 2023, DOI: 10.3389/fnmol.2023.1253040.

The most defensible current expert interpretation is that Pol III has a nonredundant role in human VZV defense, but several central questions remain unresolved: the decisive in-vivo cell type; whether cytosolic viral-DNA transcription or nuclear RNA-derived signaling predominates; how POLR3F controls neuronal latency and reactivation; whether p.Arg50Trp is fully penetrant; and which prophylactic regimen is optimal. Reviews explicitly note that POLR3-mutant patients have a narrow VZV phenotype and propose vaccination and antiviral prophylaxis, while acknowledging the absence of disease-specific trials. (cartertimofte2018rnapolymeraseiii pages 10-11)

Accordingly, the knowledge-base entry should mark the gene–disease relationship as supported by one segregating family plus functional human-cell evidence, not as a mature disorder with established epidemiology or consensus guidelines. Variant classification, MONDO/OMIM identifiers, transcript HGVS, and current population frequency should be rechecked directly in ClinVar, ClinGen, OMIM, HGNC, and gnomAD before production release.

References

1. (cartertimofte2018varicellazosterviruscns pages 6-8): Madalina E. Carter-Timofte, Anders F. Hansen, Maibritt Mardahl, Sébastien Fribourg, Franck Rapaport, Shen-Ying Zhang, Jean-Laurent Casanova, Søren R. Paludan, Mette Christiansen, Carsten S. Larsen, and Trine H. Mogensen. Varicella-zoster virus cns vasculitis and rna polymerase iii gene mutation in identical twins. Neurology Neuroimmunology & Neuroinflammation, Nov 2018. URL: https://doi.org/10.1212/nxi.0000000000000500, doi:10.1212/nxi.0000000000000500. This article has 66 citations.

2. (cartertimofte2018varicellazosterviruscns pages 4-5): Madalina E. Carter-Timofte, Anders F. Hansen, Maibritt Mardahl, Sébastien Fribourg, Franck Rapaport, Shen-Ying Zhang, Jean-Laurent Casanova, Søren R. Paludan, Mette Christiansen, Carsten S. Larsen, and Trine H. Mogensen. Varicella-zoster virus cns vasculitis and rna polymerase iii gene mutation in identical twins. Neurology Neuroimmunology & Neuroinflammation, Nov 2018. URL: https://doi.org/10.1212/nxi.0000000000000500, doi:10.1212/nxi.0000000000000500. This article has 66 citations.

3. (ansari2021primaryandacquired pages 5-6): Rahila Ansari, Lindsey B Rosen, Andrea Lisco, Don Gilden, Steven M Holland, Christa S Zerbe, Robert A Bonomo, and Jeffrey I Cohen. Primary and acquired immunodeficiencies associated with severe varicella-zoster infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 73:e2705-e2712, Aug 2021. URL: https://doi.org/10.1093/cid/ciaa1274, doi:10.1093/cid/ciaa1274. This article has 59 citations.

4. (cartertimofte2018rnapolymeraseiii pages 6-8): Madalina E. Carter-Timofte, Søren R. Paludan, and Trine H. Mogensen. Rna polymerase iii as a gatekeeper to prevent severe vzv infections. Trends in molecular medicine, 24 10:904-915, Oct 2018. URL: https://doi.org/10.1016/j.molmed.2018.07.009, doi:10.1016/j.molmed.2018.07.009. This article has 52 citations and is from a domain leading peer-reviewed journal.

5. (cartertimofte2018varicellazosterviruscns pages 3-4): Madalina E. Carter-Timofte, Anders F. Hansen, Maibritt Mardahl, Sébastien Fribourg, Franck Rapaport, Shen-Ying Zhang, Jean-Laurent Casanova, Søren R. Paludan, Mette Christiansen, Carsten S. Larsen, and Trine H. Mogensen. Varicella-zoster virus cns vasculitis and rna polymerase iii gene mutation in identical twins. Neurology Neuroimmunology & Neuroinflammation, Nov 2018. URL: https://doi.org/10.1212/nxi.0000000000000500, doi:10.1212/nxi.0000000000000500. This article has 66 citations.

6. (lata2021rnapolymeraseiii pages 21-22): Elisabeth Lata, Karine Choquet, Francis Sagliocco, Bernard Brais, Geneviève Bernard, and Martin Teichmann. Rna polymerase iii subunit mutations in genetic diseases. Frontiers in Molecular Biosciences, Jul 2021. URL: https://doi.org/10.3389/fmolb.2021.696438, doi:10.3389/fmolb.2021.696438. This article has 86 citations.

7. (cartertimofte2018rnapolymeraseiii pages 4-6): Madalina E. Carter-Timofte, Søren R. Paludan, and Trine H. Mogensen. Rna polymerase iii as a gatekeeper to prevent severe vzv infections. Trends in molecular medicine, 24 10:904-915, Oct 2018. URL: https://doi.org/10.1016/j.molmed.2018.07.009, doi:10.1016/j.molmed.2018.07.009. This article has 52 citations and is from a domain leading peer-reviewed journal.

8. (cartertimofte2018rnapolymeraseiii pages 10-11): Madalina E. Carter-Timofte, Søren R. Paludan, and Trine H. Mogensen. Rna polymerase iii as a gatekeeper to prevent severe vzv infections. Trends in molecular medicine, 24 10:904-915, Oct 2018. URL: https://doi.org/10.1016/j.molmed.2018.07.009, doi:10.1016/j.molmed.2018.07.009. This article has 52 citations and is from a domain leading peer-reviewed journal.

9. (kennedy2021recentissuesin pages 8-9): Peter Kennedy, Trine Mogensen, and Randall Cohrs. Recent issues in varicella-zoster virus latency. Viruses, 13:2018, Oct 2021. URL: https://doi.org/10.3390/v13102018, doi:10.3390/v13102018. This article has 83 citations.

10. (cartertimofte2018varicellazosterviruscns pages 1-2): Madalina E. Carter-Timofte, Anders F. Hansen, Maibritt Mardahl, Sébastien Fribourg, Franck Rapaport, Shen-Ying Zhang, Jean-Laurent Casanova, Søren R. Paludan, Mette Christiansen, Carsten S. Larsen, and Trine H. Mogensen. Varicella-zoster virus cns vasculitis and rna polymerase iii gene mutation in identical twins. Neurology Neuroimmunology & Neuroinflammation, Nov 2018. URL: https://doi.org/10.1212/nxi.0000000000000500, doi:10.1212/nxi.0000000000000500. This article has 66 citations.

11. (cartertimofte2018rnapolymeraseiii pages 1-2): Madalina E. Carter-Timofte, Søren R. Paludan, and Trine H. Mogensen. Rna polymerase iii as a gatekeeper to prevent severe vzv infections. Trends in molecular medicine, 24 10:904-915, Oct 2018. URL: https://doi.org/10.1016/j.molmed.2018.07.009, doi:10.1016/j.molmed.2018.07.009. This article has 52 citations and is from a domain leading peer-reviewed journal.

12. (lata2021rnapolymeraseiii pages 10-11): Elisabeth Lata, Karine Choquet, Francis Sagliocco, Bernard Brais, Geneviève Bernard, and Martin Teichmann. Rna polymerase iii subunit mutations in genetic diseases. Frontiers in Molecular Biosciences, Jul 2021. URL: https://doi.org/10.3389/fmolb.2021.696438, doi:10.3389/fmolb.2021.696438. This article has 86 citations.

13. (ansari2021primaryandacquired pages 21-22): Rahila Ansari, Lindsey B Rosen, Andrea Lisco, Don Gilden, Steven M Holland, Christa S Zerbe, Robert A Bonomo, and Jeffrey I Cohen. Primary and acquired immunodeficiencies associated with severe varicella-zoster infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 73:e2705-e2712, Aug 2021. URL: https://doi.org/10.1093/cid/ciaa1274, doi:10.1093/cid/ciaa1274. This article has 59 citations.

14. (ansari2021primaryandacquired pages 24-25): Rahila Ansari, Lindsey B Rosen, Andrea Lisco, Don Gilden, Steven M Holland, Christa S Zerbe, Robert A Bonomo, and Jeffrey I Cohen. Primary and acquired immunodeficiencies associated with severe varicella-zoster infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 73:e2705-e2712, Aug 2021. URL: https://doi.org/10.1093/cid/ciaa1274, doi:10.1093/cid/ciaa1274. This article has 59 citations.

15. (ansari2021primaryandacquired pages 22-23): Rahila Ansari, Lindsey B Rosen, Andrea Lisco, Don Gilden, Steven M Holland, Christa S Zerbe, Robert A Bonomo, and Jeffrey I Cohen. Primary and acquired immunodeficiencies associated with severe varicella-zoster infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 73:e2705-e2712, Aug 2021. URL: https://doi.org/10.1093/cid/ciaa1274, doi:10.1093/cid/ciaa1274. This article has 59 citations.

16. (ansari2021primaryandacquired pages 10-11): Rahila Ansari, Lindsey B Rosen, Andrea Lisco, Don Gilden, Steven M Holland, Christa S Zerbe, Robert A Bonomo, and Jeffrey I Cohen. Primary and acquired immunodeficiencies associated with severe varicella-zoster infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 73:e2705-e2712, Aug 2021. URL: https://doi.org/10.1093/cid/ciaa1274, doi:10.1093/cid/ciaa1274. This article has 59 citations.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.